Miscarriage rates study
Common Questions and Answers about Miscarriage rates study
miscarriage
All kinds of numbers and miscarriage rates are running around out there after a heart beat is seen, I have seen from 5 to 10% quoted. It sounds like you are doing all the right things and things are going great.
Hope this helps, not sure there is an answer.
(Let alone a study that rates a whole lot of women on their uterus shape and then follows up to see if their miscarriage rate is higher than average.) I don't think anyone even knows how many women have anomalous shapes of uterus, many might and it is never detected. All of the heart-shaped uterus studies I have seen have begun with a woman who has had a problem, and then they have determined that the uterus was or wasn't an unusual shape.
But once you have IVF, the statistics are the same for miscarriage. One in four pregnancies will result in miscarriage no matter the means of conception.
Female infertility related to thyroid autoimmunity: the ovarian follicle hypothesis.
Thyroid dysfunction and autoimmunity in infertile women is for study - PMID: 12490077.
I have heard that it is more difficult for a man to contract the virus from an infected female, is this correct? I have tried to find transmittal rates, but the only ones I have found are when suppressive therapy is involved. Can anyone shed any light on this for me? I am close to having sex with her, but still feel a little uneasy. Whenever we do, I will use condoms, but I understand that this is only 30-40% effective. Any advice anyone can give is greatly appreciated. Thanks!
A recent study on hsv2 that involved pcr swabbing 4x/day showed that sometimes shedding literally is just hours.
It can theoretically cause birth problems because it's a live vaccine. I'm no doctor but I did some research on the subject when getting my MMR shot in 2012. Please read the Center for Disease Control's info. A study done in the 70s and 80s didn't show an increase in Congenital Rubella Syndrome. Also the rates for miscarriage didn't increase when compared to the general population. It might make you feel better. Ask your doctor for more up to date info.
In my case, I was never happy with the SVR rates for standard treatment, especially in light of the serious side effects they produce in some people. I read a lot and follow a lot of drugs in development as many ohers here do. I decided that I am willing t take that risk with R 7128. It is still in phase 1 whereas VX 950 is in phase 3.
Only rough estimates are available. But here are some pertinent data. In a study to determine the effectiveness of antiherpetic therapy (valacylovir) to prevent transmission of HSV-2, monogamous couples who were HSV-2 discordant -- i.e. one with HSV-2, the other without it -- the rate of transmission was about 5% per year. That is, the virus was transmitted in 1 in 20 couples every 12 months. The couples had unprotected sex about 2-3 times per week.
"Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.
I went back to my PCM who referred me to a cardiologist/EP that finally listened to me. I underwent an EP Study in December and he was unable to provoke any abnormal rhythms. At that time he implanted a St. Jude ILR. I have gone now three times to have it interrogated and have been found to have had two episodes of bradycardia at 44/46 bpms and my symptoms during that time were being very, very lightheaded, sweaty and nauseous.
HSV 2 genital 15-30% of days evaluated
HSV 1 genital 3-5% of days evaluated
HSV 1 oral 25% of days evaluated
HSV 2 oral 1% of days evaluated
It's hard to transmit ghsv1 because it doesn't often recur - many people with ghsv1 only get the initial outbreak and no recurrences - and it sheds so infrequently compared to other hsv infections/locations.
Also, about half the adult population has hsv1 already, usually orally, and once you have hsv1 you can't get it again.
The success rates have been show to be lower in African Americans with pegylated interferon and ribavirin only.
With triple therapy (the addition of a protease inhibitor Victrelis or Incivek used in conjunction with pegylated interferon and ribavirin) population pharmacokinetic analysis of the protease inhibitors indicated that race had no apparent effect on exposure. In other words, viral clearance was the same with all ethnic groups.
6%) was comparable or higher than the SVR rate in treatment-naive subjects with eRVR treated with T12/PR24 in Study 108 (89.2%). In Study 106, SVR rates in prior relapsers with eRVR were equally high when they were treated with a 24-week or a 48-week regimen. These data suggest that both treatment-naive and prior relapser subjects with eRVR can shorten treatment duration with Peg-IFN/RBV by 6 months without loss of efficacy, which provides a significant safety and treatment burden benefit.
In Study 107 we observed patterns of response across the treatment-failure population, and made amendments during the course of the study in an effort to optimize treatment. The SVR rates reported here are part of our effort to identify the most appropriate regimen for this difficult-to-treat population and to show that 48-week regimens may further enhance SVR rates for certain treatment-failure patients.
//pubmed.ncbi.nlm.nih.gov/36272098/
"Confirming that once someone has HSV1 in one location on their body, itis highly unlikely they would get the virus in a new location." - yes, this is true, but I'd still avoid contact with an outbreak. I have ghsv2. I wouldn't give oral sex to someone with a ghsv2 outbreak so as to avoid getting it orally.
Nitazoxanide (NTZ) is undergoing study for treatment of chronic hepatitis C (CHC) and shows complete EVR (cEVR) rates of 68% to 86% and SVR rates of 79% and 80% in naïve genotype 4 patients. The antiviral mechanism of action of NTZ appears to be induction of PKR, a mediator of cellular antiviral responses.
Researchers also found that in the third of study participants whose ribavirin dosage was reduced as a result of anemia, cure rates actually improved to as high as 52 percent, whereas in those whose ribavirin dose stayed the same, cure rates were lower, at 37 percent.
Recommended
